Telemark Asset Management LLC Increases Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Telemark Asset Management LLC lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 25.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 500,000 shares of the company's stock after buying an additional 100,000 shares during the period. Telemark Asset Management LLC owned approximately 0.24% of Cellebrite DI worth $11,015,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CLBT. Quarry LP purchased a new position in shares of Cellebrite DI in the 3rd quarter worth approximately $27,000. Advisors Asset Management Inc. boosted its stake in shares of Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock worth $52,000 after buying an additional 1,742 shares during the last quarter. R Squared Ltd purchased a new position in shares of Cellebrite DI in the 4th quarter worth approximately $100,000. Venturi Wealth Management LLC boosted its stake in shares of Cellebrite DI by 28.6% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock worth $152,000 after buying an additional 2,000 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Cellebrite DI in the fourth quarter valued at approximately $234,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analyst Ratings Changes

CLBT has been the topic of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Monday. Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $23.43.

Remove Ads

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $17.62 on Thursday. The company has a market cap of $3.63 billion, a P/E ratio of -12.68, a P/E/G ratio of 4.27 and a beta of 1.53. The stock's fifty day moving average price is $21.58 and its two-hundred day moving average price is $19.70. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.